|Bid||168.35 x 0|
|Ask||171.85 x 0|
|Day's range||168.70 - 170.50|
|52-week range||153.10 - 202.30|
|Beta (5Y monthly)||0.64|
|PE ratio (TTM)||20.99|
|Forward dividend & yield||2.20 (1.34%)|
|Ex-dividend date||02 May 2023|
|1y target est||N/A|
Germany's Merck KGaA on Thursday predicted 2023 earnings would slip due to a decline at its electronic chemicals unit and a drop in COVID-related demand for its lab supplies from drug and vaccine makers. For 2023 earnings before interest, taxes, depreciation and amortisation (EBITDA), adjusted for one-offs, the company "assumes a moderate decline to an about stable development", before any currency swings, it said in a statement. Negative foreign exchange effects would likely be an additional drag of between 1% and 4%, according to the maker of pharmaceuticals, lab equipment and specialty chemicals.
Merck KGaA (MKGAF) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.